Totally (TLY) Share Price, News & Analysis

Company Overview

Totally plc, together with its subsidiaries, provides out-of-hospital healthcare services in the United Kingdom and Ireland. It operates through Urgent Care, Elective Care, and Corporate Wellbeing segments. The company provides urgent treatment centres which manages front door to A&E departments; NHS 111, GP out of hours services; and clinical assessment services providing telephonic access to multidisciplinary teams of clinicians, and acute visiting services as part of an integrated care system. It offers community outpatient services including specialist dermatology and referral management; physiotherapy, such as first contact practitioners delivering full musculoskeletal services at GP surgeries, to health centres, and prisons and gym environments; and podiatry services. In addition, it offers corporate fitness; wellbeing and occupational health services; provides dermatology and referral management services; coaching services to consumer; and hospital insourcing services, as well as IT healthcare solutions; and provision for online health and safety risk assessments. Totally plc was incorporated in 1999 and is based in Derby, the United Kingdom.

Key Stats

• Today's Range: 0.20 to 0.25
• 50-Day Range: 0.24 to 4.06
• 52-Week Range: 0.20 to 11.50
• Volume: 653,378 shs
• Average Volume: 2.89 million shs
• Market Capitalization: £491.37 thousand
• P/E Ratio: N/A
• Dividend Yield: 400.00%
• Price Target: GBX 20
• Consensus Rating: Buy

Totally Stock Analysis - MarketRank™

Totally scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Totally has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Totally has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Totally is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Totally is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Totally has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TLY.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Totally is a leading dividend payer. It pays a dividend yield of 13.16%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Totally does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for TLY.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.31

News Sentiment

Totally has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Totally this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Totally to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Totally insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.31% of the stock of Totally is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.33% of the stock of Totally is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TLY Stock Analysis - Frequently Asked Questions

How have TLY shares performed this year?

Totally's stock was trading at GBX 7.50 at the beginning of the year. Since then, TLY shares have decreased by 96.7% and is now trading at GBX 0.25.

How were Totally's earnings last quarter?

Totally plc (LON:TLY) announced its quarterly earnings results on Wednesday, November, 6th. The health services provider reported $0.02 EPS for the quarter. Totally had a negative trailing twelve-month return on equity of 11.01% and a negative net margin of 2.85%.

How do I buy shares of Totally?

Shares of TLY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Totally own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Totally investors own include Alibaba Group (BABA), Meta Platforms (META), Advanced Micro Devices (AMD), Bank of America (BAC), DraftKings (DKNG), Freeport-McMoRan (FCX) and Intel (INTC).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 7/08/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Care Facilities
• Sub-Industry: N/A
• Current Symbol: LON:TLY
• CIK: N/A
• Web: www.totallyplc.com
• Phone: +44-20-38663330
• Fax: N/A
• Employees: 1,668
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 20
• High Stock Price Target: GBX 20
• Low Stock Price Target: GBX 20
• Potential Upside/Downside: +7,900.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 0.83
• P/E Growth: N/A
• Net Income: -£3.79 million
• Net Margins: -2.85%
• Pretax Margin: N/A
• Return on Equity: -11.01%
• Return on Assets: -2.42%

Debt

• Debt-to-Equity Ratio: 14.73
• Current Ratio: 0.50
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: £133.05 million
• Price / Sales: 0.00
• Cash Flow: GBX 0.03 per share
• Price / Cash Flow: 9.08
• Book Value: GBX 17.28 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 196,547,008
• Free Float: N/A
• Market Cap: £491.37 thousand
• Optionable: Not Optionable
• Beta: 0.55